Abilify and Lidocaine hydrochloride drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abilify and Lidocaine hydrochloride. Common interactions include chronic kidney disease among females and electrocardiogram qt prolonged among males.

The phase IV clinical study analyzes what interactions people who take Abilify and Lidocaine hydrochloride have. It is created by eHealthMe based on reports of 15 people who take Abilify and Lidocaine hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

15 people who take Abilify and Lidocaine hydrochloride together, and have interactions are studied.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 94,501 Abilify users for its effectiveness, alternative drugs and more.

What is Lidocaine hydrochloride?

Lidocaine hydrochloride has active ingredients of lidocaine hydrochloride. It is often used in pain. eHealthMe is studying from 3,572 Lidocaine hydrochloride users for its effectiveness, alternative drugs and more.

Number of Abilify and Lidocaine hydrochloride reports submitted per year:

Common Abilify and Lidocaine Hydrochloride drug interactions by gender *:

female:

Chronic kidney disease
Pyrexia
Renal failure
Blood pressure increased
Convulsion
Death
Renal tubular necrosis

male:

Electrocardiogram qt prolonged
Gastrointestinal hypomotility
Local swelling
Major depression
Musculoskeletal stiffness
Neck pain
Oedema peripheral
Renal impairment
Scab
Skin discolouration

Common Abilify and Lidocaine Hydrochloride drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Convulsion

40-49:

Chronic kidney disease
Renal failure

50-59:

Dermatitis contact
Local swelling
Musculoskeletal stiffness
Neck pain
Oedema peripheral
Renal failure
Renal tubular necrosis
Scab
Skin discolouration
Skin exfoliation

60+:

Chronic kidney disease
Renal failure

Common conditions people have *:

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 66.67%
High Blood Pressure: 7 people, 46.67%
Hypersensitivity: 5 people, 33.33%
Gastric Ulcer (stomach ulcer): 5 people, 33.33%
Neuropathy Peripheral (surface nerve damage): 4 people, 26.67%
Cardiac Disorder: 4 people, 26.67%
Constipation: 4 people, 26.67%
Gastrointestinal Motility Disorder (abnormal intestinal contractions): 4 people, 26.67%
Heart Disease: 4 people, 26.67%
High Blood Cholesterol: 4 people, 26.67%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and Lidocaine hydrochloride?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .